Screener
Kailera Therapeutics KLRA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Kailera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026.
- Filed
- May 26, 2026, 4:29 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-239417
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | 9,376 | 1,055 |
| Operating lease liabilities | (282) | - |
| Other non-current liabilities | (69) | - |
| Net cash used in operating activities | (68,310) | (18,201) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (48,448) | (54,440) |
| Maturities of marketable securities | 71,297 | - |
| Net cash provided by (used in) investing activities | 22,849 | (54,440) |
Item 1. Financial Statements.
FAQ
- What is Kailera Therapeutics's operating cash flow?
- Kailera Therapeutics (KLRA) reported operating cash flow of -$68.31M in Q1 2026.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Kailera Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude